Iron infusion may speed recovery after heart surgery in seniors
NCT ID NCT04913649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving intravenous iron to older adults (70+) after heart surgery helps them recover from anemia and reduces disability. About 310 patients will receive either iron or a placebo. The main goal is to see if iron improves daily functioning 90 days after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 310 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
70 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Mentally competent with age ≥ 70 years * Elective AVR or CABG surgery * Expected uncomplicated postoperative trajectory, defined as: * No inotropic agents or ventilation at time of final inclusion (POD 1) * Expected discharge to general ward at POD 1 * Moderate postoperative IDA, defined as: * Hb between 85 and 110 g/L and * Ferritin \<100 µg/L or * Iron saturation (TSAT) \< 20% Exclusion Criteria: * Medical history of iron overload/haemochromatosis * Medical history of liver cirrhosis or ALT/AST value in blood serum triple of normal value (female patients: ALT \>120, AST \>105 U/L. Male patients: ALT\>150, AST\>135 U/L) * Severe renal failure (eGFR\<15ml/min/1.73m2) * Recent treatment with IVI (\<12 weeks prior) * Serious or severe allergic reaction to IVI in medical history * Severe asthma or eczema in medical history (atopic constitution)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Iron deficiency anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Amphia Hospital
RECRUITINGBreda, Netherlands
-
St Antonius Hospital
RECRUITINGNieuwegein, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can starting iron sooner protect preterm babies on donor milk?
- Can treating anemia before pregnancy stop it later?
- Can a new iron injection match the standard treatment?
- One infusion before surgery: could it cut transfusions?
- Iron and folic acid: a simple pill that could ease anemia and heart symptoms?
- A simple nutrient may shield Babies' brains from iron deficiency